Guardant Health (GH) Earnings Date & Reports

Key Takeaways

• Guardant Health (GH) is scheduled to report second-quarter 2026 results on Thursday, July 30, after the market close.
• Wall Street expects revenue of approximately $314 million, representing year-over-year growth of roughly 35%, and a non-GAAP (non-Generally Accepted Accounting Principles) loss per share of approximately $0.40.
• Investor attention will center on Shield colorectal cancer screening test volumes, which surged to roughly 44,000 tests in Q1 2026, and whether commercial momentum continued through the second quarter.
• The company raised full-year 2026 revenue guidance to $1.30–$1.32 billion following its Q1 beat, setting a high bar heading into this report.
• Shares have pulled back roughly 15% from the early-July peak of $174, but remain up more than 220% over the past twelve months, reflecting elevated expectations.

Earnings Context and Why It Matters

Guardant Health enters its second-quarter report at a pivotal moment. The precision oncology company delivered its strongest year-over-year revenue growth in five years during Q1 2026, with total revenue jumping 48% to $301.7 million. That quarter also marked the first time trailing 12-month revenue crossed the $1 billion threshold. With the Shield screening test now scaling through a nationwide Quest Diagnostics partnership, direct-to-consumer advertising, and expanding physician adoption, the Q2 update will offer the clearest read yet on whether this growth trajectory is sustainable. For investors, the report is more than a quarterly scorecard — it is a checkpoint on management's stated goal of reaching company-wide cash-flow breakeven by the end of 2027.

Earnings Expectations

Analysts polled by major data providers project Guardant Health will report second-quarter revenue in the range of $314 million to $324 million, with a consensus near $314 million — a roughly 35% increase from the $232 million recorded in the same quarter a year ago. The non-GAAP net loss per share is expected to narrow to approximately $0.40, compared with a loss of $0.44 in Q2 2025, reflecting improved gross margins and operating leverage. It is important to note that GAAP (Generally Accepted Accounting Principles) losses tend to run wider due to stock-based compensation and other non-cash items; last quarter's GAAP loss was $0.85 per share versus a non-GAAP loss of $0.45.

Key metrics beyond the headline numbers include oncology test volumes — which grew 47% year-over-year in Q1 to roughly 86,000 tests — and Shield screening volumes, which reached approximately 44,000 tests. Average selling prices (ASPs) for Guardant360 Liquid have been stable in the $3,000–$3,100 range, and any shifts in reimbursement trends will also be closely scrutinized. The company's own guidance implies Q2 revenue of roughly $320–$330 million at the midpoint of the full-year range, leaving room for a potential beat if Shield and oncology momentum held.

Historically, Guardant Health has beaten consensus revenue estimates in three of the past four quarters. Stock reactions to recent reports have been mixed: shares rose 3.7% after Q1 2026 results but fell 3.1% following Q4 2025 and dropped 9.3% after Q2 2025.

AI Screener

For investors seeking to identify opportunities across the healthcare and precision diagnostics landscape ahead of earnings season, Tickeron's AI Screener offers a streamlined way to filter thousands of stocks and ETFs (exchange-traded funds) using customizable criteria. The AI Screener is an AI-powered stock and ETF discovery tool that allows traders and investors to scan the market based on technical patterns, fundamentals, trend strength, volatility metrics, and AI-driven trading signals. Users can refine searches by industry, market capitalization, technical indicators, price patterns, and performance data — helping surface breakout candidates, trending stocks, and trade ideas far more efficiently than manual screening. Explore the AI Screener to see how data-driven filtering can sharpen your market research.

Market Reaction and Investor Sentiment

Guardant Health shares have experienced a volatile few weeks heading into the July 30 report. After touching a 52-week high of $174.08 on July 6, the stock has retreated to the mid-$140s, reflecting a degree of caution as the earnings date approaches. The pullback may also reflect broader sector rotation and profit-taking following a remarkable rally that has seen the stock more than triple from its 52-week low of roughly $40 set in mid-2025.

Analyst sentiment remains broadly constructive. The consensus rating among 25 analysts tracked by major platforms is a Strong Buy, with an average 12-month price target near $171. However, the Zacks Earnings ESP (Expected Surprise Prediction) for Guardant Health currently reads negative at -4.48%, suggesting that the most recent analyst revisions have tilted slightly downward — a factor that introduces some uncertainty into the near-term setup. Key risks heading into the print include the pace of Shield adoption relative to elevated expectations, any softening in oncology test volumes, and the company's ability to manage operating expenses, which rose 34% year-over-year in Q1 as Guardant invested heavily in commercial infrastructure.

Forward Outlook and Key Factors to Monitor

Beyond the quarterly numbers, several developments could meaningfully shape Guardant Health's trajectory through the remainder of 2026 and into 2027.

First, Shield screening remains the central growth narrative. Management guided to 230,000–245,000 Shield tests for the full year, implying a steep ramp from the 44,000 reported in Q1. The Quest Diagnostics partnership — launched late in the first quarter — is expected to meaningfully broaden physician access, and any commentary on early traction from that collaboration will be closely parsed. Additionally, potential inclusion of Shield in American Cancer Society (ACS) colorectal cancer screening guidelines remains an unresolved catalyst. Co-CEO AmirAli Talasaz noted on the Q1 call that a decision could come "any day," and positive news would likely expand Shield's addressable market considerably.

Second, the path to profitability is coming into sharper focus. Guardant ended Q1 with approximately $1.2 billion in cash and guided to full-year free cash flow burn of $185–$195 million, an improvement from $233 million in 2025. The core oncology business — excluding screening investments — is already free-cash-flow positive, and management has targeted company-wide cash-flow breakeven by the end of 2027. Investors will watch for signals on whether that timeline remains intact, particularly as the company continues reinvesting incremental Shield gross profit into commercial expansion.

Third, pipeline catalysts extend beyond screening. FDA (Food and Drug Administration) approval of Guardant360 Liquid as a companion diagnostic remains under review, and the anticipated launch of Reveal Ultra — a next-generation minimal residual disease (MRD) test — represents additional upside not embedded in current guidance. Meanwhile, MolDx (Molecular Diagnostic Services program) reimbursement decisions for breast cancer MRD testing and immunotherapy response monitoring could boost Reveal's average selling price. Any updates on these regulatory and reimbursement fronts could influence the stock's post-earnings direction as much as the headline numbers themselves.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations